<DOC>
	<DOCNO>NCT00665431</DOCNO>
	<brief_summary>We evaluate efficacy PN 400 active comparator patient Osteoarthritis knee .</brief_summary>
	<brief_title>Efficacy Study PN400 ( VIMOVO ) Twice Daily Celebrex Once Daily Patients With Osteoarthritis</brief_title>
	<detailed_description>3-Month study subject 50 year old osteoarthritis knee . Assessments Western Ontario McMaster Universities ( WOMAC ) pain function patient global assessment scale .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Antacids</mesh_term>
	<mesh_term>Anti-Ulcer Agents</mesh_term>
	<criteria>Inclusion Criteria 1 . Male nonpregnant female subjects50 year age old 6month history OA knee 2 . Female subject eligible participation study nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; childbearing potential , negative pregnancy test Screening , use adequate contraceptive method . 3 . Subjects require stable dose NSAIDs , COX2 inhibitors oral analgesic therapy least 6 week require continue treatment 12 week . Current oral analgesic therapy withdrawn Screening . 4 . Each subject require able understand comply study procedure require subject able willing provide write informed consent prior study procedure perform . 5 . Subjects require agree keep physical activity stable level throughout study . 6 . Subjects require symptomatic OA knee meeting American College Rheumatology ( ACR ) criteria clinical diagnosis OA . 7 . Subjects require ACR functional class rating I , II III . In addition , subject meet requirement OA flare Baseline/ Randomization Visit . Exclusion Criteria 1 . Subjects rheumatoid arthritis gout/pseudogout 2 . Subjects fibromyalgia syndrome 3 . Acute joint trauma index joint within 3 month prior screen active symptom 4 . Previous ( past 12 month ) anticipate need surgical invasive procedure perform index joint study 5 . Subject currently take anticipate take CoumadinÂ® , warfarin , lithium 6 . History hypersensitivity esomeprazole another PPI 7 . History allergic reaction intolerance NSAID ( include aspirin ) and/or subject history NSAIDinduced symptom asthma , rhinitis , and/or nasal polyp 8 . History allergic reaction sulfonamides 9 . Subjects intraarticular intramuscular corticosteroid intraarticular hyaluronic acid injection within 8 week prior randomization 10 . Participation study investigational treatment 4 week Screening 11 . Presence uncontrolled acute chronic medical illness , e.g . morbid obesity , GI disorder , diabetes , active GI disease , chronic acute renal hepatic disorder , depression and/or infection , etc , would endanger subject subject participate study 12 . GI disorder ( e.g. , severe erosive esophagitis , Zollinger Ellison syndrome ) surgery lead impaired drug absorption 13 . Peptic ulcer disease within 6 month prior Screening 14 . Evidence uncontrolled , unstable cardio cerebrovascular disorder , investigator 's opinion would endanger subject subject participate study 15 . Schizophrenia bipolar disorder 16 . Subjects start physical therapy index joint le 6 week prior study Screening 17 . Use excluded concomitant medication 18 . A recent history ( past 3 month ) suggestive alcohol drug abuse dependence , include overuse/abuse narcotics management pain 19 . Serious blood coagulation disorder include use systemic anticoagulant 20 . Screening laboratory value alanine aminotransferase , aspartate aminotransferase great 2 time upper limit normal 21 . Estimated creatinine clearance le 30 ml/min 22 . Other note specifically , Screening laboratory value clinically significant investigator 's opinion would endanger subject subject participate study 23 . History malignancy , treat untreated , within past 5 year , exception successfully treat basal cell squamous cell carcinoma skin 24 . Previous participation another PN 400 clinical research trial 25 . Subjects employee research facility way supervision principal investigator study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>